Liotixil

Ceftazidime, the active ingredient in Liotixil, is a third‑generation cephalosporin presented as an injectable solution for intramuscular use. It treats serious Gram‑negative infections, including Pseudomonas aeruginosa, respiratory, urinary, intra‑abdominal and other severe bacterial infections in hospitalized patients. It is indicated for respiratory tract infections, urinary tract infections and intra‑abdominal infections.

GNH USA supplies Liotixil as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products under EU regulations to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring reliable supply chains.

Ceftazidime is a third‑generation cephalosporin used to treat serious Gram‑negative bacterial infections. - Serious Gram‑negative infections: provides bacterial eradication in severe systemic infections. - Pseudomonas aeruginosa infections: effective against resistant Pseudomonas strains in hospital‑acquired cases. - Respiratory tract infections: improves outcomes in pneumonia and bronchitis caused by susceptible organisms. - Urinary tract infections: clears complicated UTIs caused by Gram‑negative pathogens. - Intra‑abdominal infections: treats peritonitis and intra‑abdominal sepsis due to susceptible bacteria.

Ceftazidime may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, sometimes watery. - Injection site pain: local discomfort or erythema. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory distress. - Stevens‑Johnson syndrome: severe skin and mucous membrane involvement. - Renal toxicity: acute kidney injury, especially in patients with pre‑existing impairment.

When using Ceftazidime, several precautions should be observed to minimize risks. - Renal function: assess and adjust dose in patients with impaired kidney function. - Allergy: avoid in individuals with known hypersensitivity to cephalosporins or penicillins. - Pregnancy: prescribe only if potential benefit justifies potential risk to the fetus. - Concomitant nephrotoxic drugs: monitor renal parameters when used with aminoglycosides or loop diuretics. - Superinfection: watch for secondary fungal or bacterial infections during prolonged therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftazidime can interact with other medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity when combined. - Loop diuretics: may potentiate ototoxicity and renal impairment. - Probenecid: reduces renal excretion of ceftazidime, raising plasma levels. Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: possible reduction in hormonal efficacy, advise additional contraception.